Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.075
USD
|
+1.42%
|
|
+10.06%
|
+35.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
126.2
|
834.3
|
585.8
|
239.2
|
180.1
|
274.7
|
-
|
-
|
Enterprise Value (EV)
1 |
126.2
|
834.3
|
585.8
|
239.2
|
180.1
|
274.7
|
274.7
|
274.7
|
P/E ratio
|
-0.91
x
|
-5.99
x
|
-3.68
x
|
-1.43
x
|
-1.47
x
|
-2.93
x
|
-2.3
x
|
-1.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
112
x
|
211
x
|
95.3
x
|
8.81
x
|
2.99
x
|
3.13
x
|
4.37
x
|
3.97
x
|
EV / Revenue
|
112
x
|
211
x
|
95.3
x
|
8.81
x
|
2.99
x
|
3.13
x
|
4.37
x
|
3.97
x
|
EV / EBITDA
|
-
|
-
|
-
|
-1.51
x
|
-1.39
x
|
-4.34
x
|
-2.76
x
|
-
|
EV / FCF
|
-1,106,046
x
|
-14,915,568
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
105,166
|
154,779
|
156,204
|
163,829
|
227,122
|
255,562
|
-
|
-
|
Reference price
2 |
1.200
|
5.390
|
3.750
|
1.460
|
0.7930
|
1.075
|
1.075
|
1.075
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/14/22
|
3/6/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.122
|
3.958
|
6.149
|
27.15
|
60.28
|
87.81
|
62.82
|
69.16
|
EBITDA
1 |
-
|
-
|
-
|
-157.9
|
-129.9
|
-63.3
|
-99.7
|
-
|
EBIT
1 |
-139.8
|
-133.4
|
-162.2
|
-164
|
-139.7
|
-86.89
|
-134.1
|
-148.6
|
Operating Margin
|
-12,457.22%
|
-3,370.52%
|
-2,638.58%
|
-603.97%
|
-231.82%
|
-98.95%
|
-213.44%
|
-214.8%
|
Earnings before Tax (EBT)
1 |
-136.9
|
-129.9
|
-157.3
|
-163
|
-112.5
|
-81.24
|
-141.8
|
-144.9
|
Net income
1 |
-137.2
|
-130.1
|
-158.1
|
-165.5
|
-113.9
|
-88.18
|
-129.5
|
-146.2
|
Net margin
|
-12,225.04%
|
-3,286.81%
|
-2,570.99%
|
-609.46%
|
-188.9%
|
-100.41%
|
-206.15%
|
-211.34%
|
EPS
2 |
-1.320
|
-0.9000
|
-1.020
|
-1.020
|
-0.5400
|
-0.3667
|
-0.4667
|
-0.6500
|
Free Cash Flow
|
-114.1
|
-55.93
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-10,169.25%
|
-1,413.14%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/14/22
|
3/6/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.203
|
1.417
|
3.575
|
5.538
|
7.007
|
11.03
|
47.6
|
5.13
|
7.319
|
0.231
|
20.48
|
25.67
|
14.88
|
26.8
|
15.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-42.18
|
-42.86
|
-49.98
|
-43.75
|
-42.99
|
-27.24
|
1.656
|
-44.91
|
-46.63
|
-49.86
|
-23.58
|
-16.58
|
-29.68
|
-17.08
|
-32.4
|
Operating Margin
|
-3,506.32%
|
-3,024.98%
|
-1,398.07%
|
-790.03%
|
-613.53%
|
-247.03%
|
3.48%
|
-875.4%
|
-637.15%
|
-21,582.68%
|
-115.12%
|
-64.59%
|
-199.46%
|
-63.71%
|
-203.77%
|
Earnings before Tax (EBT)
1 |
-42.19
|
-38.65
|
-49.63
|
-44.05
|
-41.02
|
-28.26
|
1.661
|
-20.71
|
-44.91
|
-48.57
|
-22.14
|
-15.41
|
-28.19
|
-15.54
|
-32.3
|
Net income
1 |
-42.4
|
-38.86
|
-50.26
|
-44.52
|
-41.42
|
-29.25
|
1.036
|
-21.39
|
-45.6
|
-47.92
|
-23.35
|
-18.16
|
-28.62
|
-18.06
|
-32.3
|
Net margin
|
-3,524.61%
|
-2,742.27%
|
-1,406.01%
|
-803.9%
|
-591.14%
|
-265.23%
|
2.18%
|
-416.94%
|
-623.05%
|
-20,743.29%
|
-114.01%
|
-70.74%
|
-192.37%
|
-67.4%
|
-203.14%
|
EPS
2 |
-0.3000
|
-0.2400
|
-0.3000
|
-0.0500
|
-0.0400
|
-0.1800
|
-
|
-0.1200
|
-0.0300
|
-0.2400
|
-0.0833
|
-0.0933
|
-0.0967
|
-0.0933
|
-0.1400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/14/22
|
5/9/22
|
8/4/22
|
11/8/22
|
3/6/23
|
5/12/23
|
8/9/23
|
11/8/23
|
3/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-114
|
-55.9
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.59
|
2.34
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
141.89%
|
59.15%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/14/22
|
3/6/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
1.075
USD Average target price
3.6
USD Spread / Average Target +234.88% Consensus |
1st Jan change
|
Capi.
|
---|
| +35.56% | 275M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|